The perfect combination of stem cells and blockchain

本篇文章3185字，读完约8分钟

Epochal Cell recently completed its first round of financing based on blockchain. The A round of financing led by CellGenix will be used for the treatment of coronary microvascular dysfunction (CMD), severe limb ischemia (CLI) and diabetic nephropathy (DKD) with CD34+ cell technology.

Epochal Cell is a clinical-stage biopharmaceutical company focusing on the discovery, development and commercialization of cell therapies aimed at reversing diseases and promoting the regeneration of damaged tissues. The company is developing first-class therapies based on the properties of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvascular systems. The company's platform technology uses these cells and uses unique formulas for each medical indication to achieve the body's natural repair mechanisms. .

Charles Nicholson, President and CEO of Epochal Cell, said: “The reason why stem cells have attracted much attention is that they are effective in the treatment of some difficult diseases. For example, coronary microvascular dysfunction (CMD), CD34+ cells can be used in the body’s natural healing process. It plays an important role and has the ability to promote the development and formation of a new microvascular system, thereby causing oxygen-rich blood to flow to the heart area lacking sufficient oxygen. Importantly, because it is self-cells, there will be no immune rejection. The effect will be very good. In the future, we can see again; Parkinson’s patients may not be able to walk, I will let you walk smoothly again. This is a treatment that will disrupt the era. This is regenerative medicine. I think in the next 3-5 years There will be an explosion. This is the future we see."

The global stem cell market is huge. According to Market Research and Transparency Market Research, the global market is expected to exceed US$170 billion in 2020. From the perspective of market distribution, North America is the world’s largest stem cell market, with Western Europe and Asia Pacific accounting for 38 markets respectively. % And 17%. At present, the global registered stem cell clinical research projects are mainly adult stem cell clinical trials, involving blood diseases, tumors, neurological diseases, heart diseases, immune system diseases and other fields. Among them, the United States maintains an absolute leading position, and China, Germany, France and other countries are tight Subsequently, in Asia, China, South Korea, and Japan became hotspots for stem cell research.

Charles Nicholson said: "I hope that more listed pharmaceutical companies will join us, and we will be able to promote the implementation of the treatment plan as soon as possible together and be clinically applied, so that patients can benefit as soon as possible."

Epochal Cel is applying our proprietary CD34+ cell technology to potentially treat a variety of diseases caused by potential ischemic injury, including but not limited to coronary microvascular dysfunction (CMD), severe limb ischemia (CLI) and diabetic nephropathy (DKD), these indications represent the main areas of clinical demand, presenting a large number of business opportunities.